Form 8-K - Current report:
SEC Accession No. 0000950170-25-000092
Filing Date
2025-01-02
Accepted
2025-01-02 07:08:18
Documents
13
Period of Report
2025-01-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kpti-20250102.htm   iXBRL 8-K 72941
2 EX-10.1 kpti-ex10_1.htm EX-10.1 42424
3 GRAPHIC img174362186_0.jpg GRAPHIC 2955
  Complete submission text file 0000950170-25-000092.txt   255001

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250102.xsd EX-101.SCH 30859
15 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250102_htm.xml XML 4700
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 25500213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)